Milestones & Awards

2

0

1

9

Honoured with “Most Innovative Small and Medium-sized Pharmaceutical Enterprises Award in the Asia Pacific Region 2019” by Clarivate Analytics

Successfully raised approximately US$50 million through the private placement of series A preferred shares of China Ophthalmology Focus Limited in May 2019

Formation of Lee’s Pharmaceutical Taiwan Limited, registered and operated in Taiwan

Official launch of Sancuso® in China

Official launch of Rasilez® in China

Official launch of VSL#3® in China

Honoured with “Most Growing Award” at “China Enterprise Excellence Awards Ceremony 2019”

Honoured with "2019 China 2nd Future Unicorn Competition Top 10 in China"

2

0

1

8

Completed the merger of CVie Therapeutics Limited with Windtree Therapeutics, Inc. in December 2018

Honoured with "The Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area"

Dr. Benjamin Li was honoured with “The 16th World Outstanding Chinese Award" by World Chinese Business Investment Foundation

2

0

1

7

Official launch of Mictonorm® in China

Establishment of China Ophthalmology Focus Limited

Completed the acquisition of majority of shares in Windtree Therapeutics, Inc. at a consideration of US$10 million in November 2017

Successfully carried out the reorganization of CVie Therapeutics Company Limited into two companies: CVie Therapeutics Limited for Taiwan business and CVie Therapeutics Company Limited for China business

Successfully raised approximately US$7.5 million through the private placement of series A preferred shares of CVie Therapeutics Limited in May 2017

Honoured with "Best Listed Companies Category 2017" by Forbes

2

0

1

5

Successfully raised approximately HK$383 million through the placement of new shares of the Company in April 2015

Formation of Lee’s Healthcare Industry Fund L.P. with a maximum fund size of US$20.2 million in August 2015

Inclusion to MSCI China Indexes

Inclusion to various Hang Seng Family of Indexes

Honoured with “Asia’s 200 Best Under a Billion” 2015 by Forbes

Formation of Zhaoke Pharmaceutical (Guangzhou) Company Limited, registered and operated in Nansha District, Guangzhou, China

Establishment of Guangzhou Zhaokang Hospital Company Limited and acquisition of the land parcel with a total site area of approximately 36,656 m² and with a total planned gross floor area of approximately 65,981m² specifically for medical and sanitary use in Nansha District, Guangzhou, China in September 2015

Dr Benjamin Li was honoured with "EY Entrepreneur of The Year 2015 China" by EY

2

0

1

4

Official launch of Remodulin® in China

Formation of China Oncology Focus Limited with the management of the Company

2

0

1

3

Official launch of Oral L-Carnitine® in China

Honoured with “Asia’s 200 Best Under a Billion” 2013 by Forbes

Successfully raised approximately US$3 million through the private placement of series A-2 preferred shares of CVie Therapeutics Company Limited in March 2013

Successfully raised approximately US$10 million through the private placement of series B preferred shares of CVie Therapeutics Company Limited in August 2013

2

0

1

2

Official launch of Zanidip® in China

Successfully raised approximately HK$152 million through the placement of new shares of the Company to GL Trade Investment Limited in May 2012

Establishment of China Cardiovascular Focus Limited and CVie Therapeutics Company Limited

Successfully raised approximately US$4 million through the private placement of series A-1 preferred shares of CVie Therapeutics Company Limited in July 2012

Honoured with“Technology Achievement Award 2012” by Hong Kong Awards for Industries

Honoured with “Asia’s 200 Best Under a Billion” 2012 by Forbes

2

0

1

Honoured with “Asia’s 200 Best Under a Billion” 2011 by Forbes

Honoured with "500 Best in Asia Pacific 2011" by Deloitte

2

0

1

0

Successfully raised approximately HK$40 million through the placement of new shares of the Company to an investor in October 2010

Successfully transfer of listing from GEM to Main Board of the Stock Exchange of Hong Kong Limited (Stock code: 950) on 14 May 2010

Establishment of Powder Pharmaceuticals, Incorporated

Honoured with "500 Best in Asia Pacific 2010" by Deloitte

Honoured with "Hong Kong Outstanding Enterprises 2010" by Economic Digest

2

0

9

Successfully raised approximately HK$19 million through the placement of new shares of the Company to an investor in August 2009

2

0

8

Official launch of Eyprotor® in China

2

0

6

Official launch of Slounase® in China

2

0

5

Completed the acquisition of the interests in Zhaoke Pharmaceutical (Hefei) Company Limited from the PRC partner and became a wholly owned subsidiary of the Group

2

0

4

Successfully raised approximately HK$24 million through the placement of new shares and unlisted warrants of the Company to an investor in August 2004

2

0

3

Official launch of Carnitene® in China

2

0

2

Lee’s Pharmaceutical Holdings Limited announced listing of Initial Public Offering of shares on the Growth Enterprise Market (“GEM”) of the Stock Exchange of Hong Kong Limited and the shares commenced trading on 15 July 2002

2

0

1

Official launch of Yallaferon® in China

1

9

8

Official launch of Livaracine® in China

1

9

7

Official launch of Defibrase® in China

1

9

4

Establishment of the Group

Formation of Zhaoke Pharmaceutical (Hefei) Company Limited with a PRC partner, registered and operated in Hefei City, Anhui Province, China

About Us

Milestones & Awards